We further tested the association between the levels of expression of SEMA3s with patient overall survival in 30 cancer types, and found that the direction of association is also cancer type dependent, but in general SEMA3A and SEMA3E were mainly associated with poor prognosis, and SEMA3G was associated with better survival, while the rest of the SEMA3s had an antagonistic association with survival (both advantage and disadvantage). This evidence concerns the gene SEMA3A and cancer.